TBCI 90
Alternative Names: TBCI-90Latest Information Update: 21 Oct 2020
At a glance
- Originator FibroGenesis
- Class Antineoplastics; Fibroblast cell therapies; Immunotherapies
- Mechanism of Action Cell replacements; Dendritic cell modulators; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 Oct 2020 FibroGenesis has patents pending for fibroblast cell therapy technologies as an immunotherapy, for the treatment of Cancers worldwide (FibroGenesis' website, October 2020)
- 21 Oct 2020 Preclinical trials in Cancer in USA (unspecified route) before October 2020 (FibroGenesis' pipeline, October 2020)